ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 2414
    A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
  • Abstract Number: 1484
    A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
  • Abstract Number: 1871
    A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
  • Abstract Number: 2217
    A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
  • Abstract Number: 2302
    A Specific Molecular Profiling of Secreted Rheumatoid Factors in Sjögren’ S Disease Patients with Lymphoma
  • Abstract Number: 1358
    A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
  • Abstract Number: 2032
    A Systematic Review of Treatment Strategies in VEXAS Syndrome
  • Abstract Number: 1041
    A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis
  • Abstract Number: 1791
    A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function
  • Abstract Number: 0544
    A Two-year Comparison of Spinal and Hip Mobility Between Axial Spondyloarthritis and Chronic Back Pain Patients in the SPondyloArthritis Caught Early (SPACE) Cohort
  • Abstract Number: 0694
    A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
  • Abstract Number: 1642
    A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
  • Abstract Number: L14
    A Withdrawal Study of Colchicine in Behçet Syndrome
  • Abstract Number: L12
    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity
  • Abstract Number: 1851
    Aberrant Tfh Cells Generated by Th17 Cell Plasticity in the Gut Promote Autoimmune Arthritis
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 182
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology